EGFR and cancer: Studies have revealed that mutations of kinase domains may facilitate EGFR dimerization, which in turn could promote kinase activity which gives rise to constitutive aberrant survival signals.13 Tyrosine kinase inhibitor (TKI) could inhibit this kinase activity effectively, block its downstream survival signals, and lead to cancer cell death.14 Thus, these survival signals raised by mutant EGFR have been reported to be oncogenic and tumor driver; however, the exact mechanism is still obscure.